The European Commission approved Amneal's Adcomfo®, a biosimilar to XOLAIR®, for asthma and chronic rhinosinusitis treatments.
Quiver AI Summary
Amneal Pharmaceuticals announced that the European Commission has granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®, following its approval by the UK's Medicines and Healthcare products Regulatory Agency in March 2026. Developed by Kashiv BioSciences in partnership with Alvotech, Adcomfo is intended for treating severe persistent allergic asthma in patients aged six and older, as well as adults with chronic rhinosinusitis and chronic spontaneous urticaria. The approval is based on substantial clinical data showing its efficacy and safety compared to XOLAIR. Amneal, which acquired Kashiv in August 2026, views this approval as a significant milestone in expanding access to affordable biologic medicines and its biosimilars portfolio. The U.S. application for Adcomfo is currently under review by the FDA.
Potential Positives
- Amneal Pharmaceuticals has received marketing authorization from the European Commission for Adcomfo®, a biosimilar to XOLAIR®, expanding its presence in European markets.
- The approval follows a positive opinion from the European Medicines Agency, reinforcing confidence in Amneal's product development capabilities.
- Adcomfo® is positioned as an add-on treatment for multiple severe allergic conditions, potentially broadening the patient base and increasing market opportunities for Amneal.
- The U.S. application for Amneal's proposed biosimilar to XOLAIR® is currently under review, suggesting future growth potential in the U.S. market.
Potential Negatives
- Adcomfo is associated with potential serious adverse reactions, including a Boxed Warning for anaphylaxis, which may pose liability and reputational risks for Amneal.
- The requirement for patients to be carefully selected for self-administration suggests potential challenges in the product's market acceptance and usability.
- The U.S. application for the proposed biosimilar of XOLAIR is still under review, which creates uncertainty regarding its future market entry and revenue generation for Amneal.
FAQ
What is Adcomfo® and its relation to XOLAIR®?
Adcomfo® is a biosimilar to XOLAIR®, designed to treat severe allergic asthma and chronic urticaria.
When did the European Commission approve Adcomfo®?
The European Commission granted marketing authorization for Adcomfo® on November 17, 2026.
What conditions does Adcomfo® treat?
Adcomfo® is approved for severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria.
Who developed Adcomfo®?
Adcomfo® was developed by Kashiv BioSciences in collaboration with Alvotech, and Amneal Pharmaceuticals acquired Kashiv in August 2026.
What is the status of Adcomfo® in the U.S.?
Amneal's Biologics License Application for Adcomfo® is currently under review by the U.S. Food and Drug Administration.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMRX Insider Trading Activity
$AMRX insiders have traded $AMRX stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $AMRX stock by insiders over the last 6 months:
- JASON B. DALY (EVP, Chief Legal Officer) has made 0 purchases and 2 sales selling 216,613 shares for an estimated $3,771,050.
- NIKITA SHAH (Executive Vice President) sold 146,403 shares for an estimated $2,563,516
- JOHN KIELY sold 50,000 shares for an estimated $882,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AMRX Revenue
$AMRX had revenues of $862.7M in Q3 2026. This is an increase of 9.96% from the same period in the prior year.
You can track AMRX financials on Quiver Quantitative's AMRX stock page.
You can access data on AMRX stock through the Quiver Quantitative API.
$AMRX Hedge Fund Activity
We have seen 192 institutional investors add shares of $AMRX stock to their portfolio, and 177 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 5,874,986 shares (+525.2%) to their portfolio in Q3 2026, for an estimated $118,322,218
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 3,328,258 shares (-94.9%) from their portfolio in Q3 2026, for an estimated $67,031,116
- INVESCO LTD. added 2,463,042 shares (+70.3%) to their portfolio in Q3 2026, for an estimated $49,605,665
- TRI LOCUM PARTNERS LP added 2,326,733 shares (+inf%) to their portfolio in Q3 2026, for an estimated $46,860,402
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 2,147,450 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $43,249,643
- D. E. SHAW & CO., INC. removed 1,887,799 shares (-70.9%) from their portfolio in Q2 2026, for an estimated $32,677,800
- RUBRIC CAPITAL MANAGEMENT LP removed 1,631,905 shares (-16.0%) from their portfolio in Q3 2026, for an estimated $32,866,566
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AMRX Analyst Ratings
Wall Street analysts have issued reports on $AMRX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 11/05/2026
- JP Morgan issued a "Overweight" rating on 11/04/2026
- Oppenheimer issued a "Outperform" rating on 09/23/2026
- Barclays issued a "Overweight" rating on 09/17/2026
- UBS issued a "Buy" rating on 08/03/2026
To track analyst ratings and price targets for $AMRX, check out Quiver Quantitative's $AMRX forecast page.
$AMRX Price Targets
Multiple analysts have issued price targets for $AMRX recently. We have seen 5 analysts offer price targets for $AMRX in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Daniel Clark from Leerink Partners set a target price of $25.0 on 11/05/2026
- Chris Schott from JP Morgan set a target price of $25.0 on 11/04/2026
- Les Sulewski from Oppenheimer set a target price of $27.0 on 09/23/2026
- Glen Santangelo from Barclays set a target price of $20.0 on 09/17/2026
- Ashwani Verma from UBS set a target price of $25.0 on 08/03/2026
Full Release
- European Commission approval follows UK MHRA authorization of Adcomfo in March 2026
- U.S. application for proposed biosimilar of XOLAIR ® currently under review
BRIDGEWATER, N.J., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the European Commission (EC) has granted marketing authorization for Adcomfo ® (omalizumab), a biosimilar to XOLAIR ® .
Adcomfo, also known as ADL-018/AVT23, was developed by Kashiv BioSciences LLC in collaboration with Alvotech. Amneal acquired Kashiv in August 2026. The European Commission approval follows the positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2026. Separately, Adcomfo received authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in March 2026. Together, these approvals represent important regulatory milestones for the program and expand Adcomfo’s reach across European markets.
“Adcomfo approval by the European Commission is a proud achievement, reflecting years of scientific expertise, dedication and collaboration,” said Andy Boyer, Executive Vice President and Chief Commercial Officer – Affordable Medicines. “This approval further demonstrates the strength of the capabilities supporting our expanding biosimilars portfolio. We see significant opportunity to broaden access to high-quality, affordable biologic medicines while building biosimilars into a durable, long-term growth driver for Amneal.”
Adcomfo is approved as an add-on treatment for severe persistent allergic asthma in eligible patients six years of age and older; as add-on therapy with intranasal corticosteroids for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom intranasal corticosteroid therapy does not provide adequate disease control; and as add-on therapy for adults and adolescents 12 years of age and older with chronic spontaneous urticaria (CSU) who have an inadequate response to H1 antihistamine treatment. Adcomfo is approved in 75 mg, 150 mg and 300 mg presentations in pre-filled syringe and 75 mg and 150 mg pre-filled pen configurations.
The approval is supported by a comprehensive analytical and clinical data package demonstrating biosimilarity to reference XOLAIR. The clinical development program included two key studies. The first was a randomized, double-blind, three-arm parallel group, single dose study comparing the pharmacokinetic, pharmacodynamic, safety and immunogenicity of ADL-018 with EU-approved XOLAIR in healthy adults. The second was a randomized, double-blind, multicenter confirmatory study evaluating the efficacy, safety and immunogenicity of ADL-018 compared with XOLAIR in patients with CSU. The study enrolled 600 patients and met its primary efficacy endpoint, demonstrating equivalent efficacy based on change from baseline in weekly Itch Severity Score at Week 12, with comparable safety between treatment groups.
Through the clinical studies conducted in different indications, the most commonly reported adverse reactions were headache, pyrexia, upper abdominal pain, dizziness, arthralgia and injection site reactions. Most of the reactions were mild or moderate in severity.
In Europe, ADVANZ PHARMA holds the marketing authorization and regional commercialization rights for Adcomfo through its partnership with Alvotech.
In the U.S., Amneal’s Biologics License Application (BLA) for its proposed biosimilar to XOLAIR (omalizumab) is currently under review by the U.S. Food and Drug Administration.
About Adcomfo
®
Adcomfo (omalizumab) is a biosimilar to XOLAIR, a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE) and prevents binding of IgE to FcɛRI (high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the allergic cascade.
Adcomfo ® (omalizumab) is associated with potential serious adverse reactions, including a Boxed Warning for anaphylaxis. Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and angioedema, may occur after the first dose or after more than one year of treatment and can be life-threatening. In addition, cardiovascular and cerebrovascular events and vasculitis have been identified as potential serious adverse reactions associated with Adcomfo ® .
Through the clinical studies conducted in different indications, the most commonly reported adverse reactions were headache, pyrexia, upper abdominal pain, dizziness, arthralgia and injection site reactions. Most of the reactions were mild or moderate in severity.
Omalizumab should be initiated in an appropriate healthcare setting with patient monitoring and readiness to manage anaphylaxis. Patients should be educated on the signs and symptoms of severe allergic reactions and instructed to seek immediate medical attention if they occur. Careful patient selection is recommended for self-administration.
Note: XOLAIR ® is a registered trademark of Novartis AG.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.
Investor Contact
Anthony DiMeo
VP, Investor Relations
[email protected]
Media Contact
Brandon Skop
Sr. Director, Corporate Communications
[email protected]